ReviewRadiation and environmental biophysics2022
Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides.
Review in Radiation and environmental biophysics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- Emerging role of radiopharmaceutical therapy in oncology: advances, challenges, and future directions.JNCI cancer spectrum · 2026Review
- Digital Twin Technology In Radiology.Journal of imaging informatics in medicine · 2026Review
- Fit for purpose: German contributions to the new ICRP recommendations.Radiation and environmental biophysics · 2026Review
- Review
- Evaluation of relative biological effectiveness ofEJNMMI physics · 2025Article
- Do we need dosimetry for the optimization of theranostics in CNS tumors?Neuro-oncology · 2024Review
- A clustering tool for generating biological geometries for computational modeling in radiobiology.Physics in medicine and biology · 2024Article
- 3D small-scale dosimetry and tumor control ofScientific reports · 2024Article
- Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics.Theranostics · 2024Article
- Theranostic digital twins: Concept, framework and roadmap towards personalized radiopharmaceutical therapies.Theranostics · 2024Review
- Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer.Theranostics · 2024Review
- The application of radionuclide therapy for breast cancer.Frontiers in nuclear medicine · 2023Review
- Effects of spatial variation in dose delivery: what can we learn from radon-related lung cancer studies?Radiation and environmental biophysics · 2022Review
- Correction to: Out‑of‑field effects: lessons learned from partial body exposure.Radiation and environmental biophysics · 2022Article
- The 2020 MELODI workshop on the effects of spatial and temporal variation in dose delivery.Radiation and environmental biophysics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterogeneity of dose distribution has been shown at different spatial scales in diagnostic nuclear medicine. In cancer treatment using new radiopharmaceuticals with alpha-particle emitters, it has shown an extensive degree of dose heterogeneity affecting both tumour control and toxicity of organs at risk. This review aims to provide an overview of generalized internal dosimetry in nuclear medicine and highlight the need of consideration of the dose heterogeneity within organs at risk. The current methods used for patient dosimetry in radiopharmaceutical therapy are summarized. Bio-distribution and dose heterogeneities of alpha-particle emitting pharmaceutical
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.